Morphées : Classification et prise en charge

Annales de Dermatologie et de Venereologie

Volumn 125, Issue 4, 1998, Pages 283-290

  Salmon Ehr, V ^a   Eschard, C ^a   Kalis, B ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AZATHIOPRINE; CALCITRIOL; CLOBETASOL PROPIONATE; COLCHICINE; COLLAGEN; COLLAGENASE; CORTICOSTEROID; CYCLOSPORIN A; DIMETHYL SULFOXIDE; EDETATE DISODIUM; ETRETINATE; GRISEOFULVIN; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; ISOTRETINOIN; METHOXSALEN; PENICILLAMINE; PENICILLIN G; PHENYTOIN; RECOMBINANT GAMMA INTERFERON; RETINOID; SALAZOSULFAPYRIDINE; TRIAMCINOLONE;

ARTICLE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG MECHANISM; HEMIFACIAL ATROPHY; HUMAN; MORPHEA; PATHOPHYSIOLOGY; PLASMAPHERESIS; PUVA; CLASSIFICATION; LOCALIZED SCLERODERMA; REVIEW;

HUMANS; SCLERODERMA, LOCALIZED;

EID: 0031979074     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (94)

1. Rodnan GP. When is scleroderma not scleroderma ? Bull Rheum Dis 1981:31:7-10.
2. Rodnan GP, Jablonska S, Medsger TA. Classification and nomenclature of progressive systemic sclerosis (scleroderma). Clin Rheum Dis 1979:5:5-13.
3. Peterson LS, Nelson AM, Su WPD. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995:70:1068-76.
4. Kencka D, Blaszczyk M, Jablonska S. Atrophoderma Pasini-Pierini is a primary atrophie abortive morphea. Dermatology 1995;190:203-6.
5. Murphy PK, Hymes SR, Fenske NA. Concomitant unilateral idiopathic atrophoderma of Pasini and Pierini and Morphea. Int J Dermatol 1990:29:281-3.
6. Akintewe TA, Alabi GO. Scleroderma presenting with multiple keloids. Br Med J 1985 ;291:448-9.
7. Shono S, Imura M, Ota M, Osaku A, Shinomiya S, Toda K. Lichen sclerosus et atrophicus, morphea, and coexistence of both diseases: histological studies using lectins. Arch Dermatol 1991; 127:1352-6.
8. Ditto J, Santa Cruz DJ, Bauer EA, Eisen AZ. Morphea and lichen sclerosus et atrophicus. J Am Acad Dermatol 1980;3:271-9.
9. Patterson JAK, Ackerman AB. Lichen sclerosus et atrophicus is not . related to morphea. A clinical and histologie study of 24 patients in whom both conditions were reputed to be present simultaneously. Am J Dermatopathol 1984:6:323-35.
10. Lampert A, Fortier-Beaulieu M, Thomine E, Young P, Lauret P. Association sur un membre d'un lichen scléreux et d'une sclérodermie monomélique. Ann Dermatol Venereol 1995, 122:102-4.
11. Christianson HB, Dorsey CS, O'Leary PA, Kierland RR. Localized scleroderma. A clinical study of 235 cases. Arch Dermatol 1956:74:629-39.
12. Russel DC, Maloney A, Muir AL. Progressive generalised scleroderma: respiratory failure from primary chest wall involvement. Thorax 1981;36:219-20.
13. Morrow PA. A case of symmetrical morphoea attended with the formation of bullae and extensive ulceration. J Cutan Genito-Urin Dis 1896:14:419-27.
14. Daoud MS, Su WPD, Leiferman KM, Perniciaro C. Bullous morphea: clinical, pathologic, and immunopathologic evaluation of thirteen cases. J Am Acad Dermatol 1994;30:937-43
15. O'Leary PA. In discussion on morphea. Arch Dermatol Syphilol 1954;70:387-8.
16. Templeton HJ. Localized scleroderma with bullae. Arch Dermatol Syphilol 1941;43:360-5.
17. Kornreich HK, King KK, Bernstein BH, Singscn BH, Hanson V. Scleroderma in childhood. Arthritis Rheum 1977:20:343-50.
18. Taylor DV. A case of atrophy of the mandible associated with scleroderma. Br Dent J 1949:87:246.
19. Long PR, Miller OF. Linear scleroderma. J Am Acad Dermatol 1982:7:541-4.
20. rd International Congress of Plastic Surgery. Amsterdam. Excerpta Medica 1963,66:681.
21. Klene C, Massicot P, Fcrriere-Fontan I, Sarlangue J, Fontan D, Guillard JM. Sclérodermie en coup de sabre et hémi-atrophie faciale de Parry-Romberg. Problème nosologique. Complication neurologique. Ann Pédiatr 1989:36:123-5.
22. Wartenberg R. Progressive facial hemiatrophy. Arch Neurol Psychiatry 1945:54:75-96.
23. Degos R. Les sclérodermies. In: Dermatologie. Paris: Flammarion 1981:674-83.
24. Su WPD, Person JR. Morphea profunda: a new concept and a histopathologic study of 23 cases. Am J Dermatopathol 1981;3:251-60.
25. Person JR, Su WPD. Subcutaneous morphoea: a clinical study of sixteen cases. Br J Dermatol 1979;100:371-80.
26. Shulman LE. Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome ? J Rheumatol 1974;1(Suppl):46.
27. Doyle JA, Ginsburg WW. Eosinophilic fasciitis. Med Clin North Am 1989;73:1157-66.
28. Michel CJ, Doyle JA, Ginsburg WW. Eosinophilic fasciitis: report of 15 cases. Mayo Clin Proc 1981:56:27-34.
29. Moore TL, Zucker J. Eosinophilic fasciitis. Semin Arthritis Rheum 1980:9:228-35.
30. Lakhanpal S, Ginsburg WW, Michel CJ, Doyle JA, Moore SB. Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 1988:17:221-31.
31. Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphea of children. Arch Dermatol 1980:116:169-73.
32. Rowcll NR. Acral pansclerotic morphoea with intractable pain. In: Clinical Dermatology: The CMO Case Collection/World Congress of Dermatology. Berlin: Scheltauer, 1987:178-80.
33. Curtis AC, Jansen TG. The prognosis of localized scleroderma. Arch Dermatol 1958;78:749-57.
34. Korting GW, Brachtel R. Zur Raynaud-symptomatik bei circumscripter sklerodermie. Hautarzt 1972:23:273-5.
35. Falanga V, Medsger TA, Reichlin M, Rodnan GP. Linear scleroderma: clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med 1986:104:849-57.
36. Torok E, Ablonczy E. Morphoea in children. Clin Exp Dermatol 1986:11:607-12.
37. Fleischmajer R, Perlish JS, Reeves JRT. Cellular infiltrates in scleroderma skin. Arthrit Rheum 1977;20:975-84.
38. Salmon-Ehr V, Serpier H, Nawrocki B, Cillery P, Clavel C, Birembaut P, Kalis B, Maquart FX. Increased expression of interleukin4 in scleroderma skin and scleroderma fibroblasts cultures: potential role in fibrosis. Arch Dermatol 1996;132:802-7.
39. Krafchik BR. Localized cutaneous scleroderma. Semin Dermatol 1992:11:65-72. '
40. Falanga V, Medsger TA, Reichlin M. Antinuclear and anti-singlestranded DNA antibodies in morphea and generalized morphea. Arch Dermatol 1987:123:350-3.
41. Parodi A, Drosera M, Barbieri L, Rebora A. Antihistone antibodies in scleroderma. Dermatology 1995:191:16-8.
42. Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol 1994;31:567-71.
43. Takehara K, Moroi Y, Nakabayashi Y, Ishibashi Y. Antinuclear antibodies in localized scleroderma. Arthritis Rheum 1983;26:612-6.
44. Stefanato CM, Gorkiewicz-Petkow A, Jarzabek-Chorzelska M, Jablonska S, Chorzelski T. Morphea with high titer of fibronectin antibodies. Int J Dermatol 1992;31:190-2.
45. Hulsmans RFHJ, Asghar SS, Siddiqui AH, Cormane RH. Hereditary deficiency of C2 in association with linear scleroderma « en coup de sabre ». Arch Dermatol 1986;122:76-9.
46. Giordano M, Ara M, Valentini G, Chianese U, Bencivenga T. Presence of eosinophilia in progressive systemic sclerosis and localized scleroderma. Arch Dermatol Res 1981;271:411-7.
47. Studer A, Hunziker T, LUtolf O, Schmidli J, Chen D, Mahler F. Quantitative nailfold capillary microscopy in cutaneous and systemic lupus erythematosus and localized and systemic scleroderma. J Am Acad Dermatol 1991;24:941-5.
48. Kalis B, De Rigal J, Léonard F, Lévêque JL, Riche O, Le Corre Y, De Lacharrière O. In vivo study of sclcroderma by non-invasive techniques. Br J Dermatol 1990;122:785-92.
49. Bourgeois P, Aeschlimann A., Bourgeois-Droin C. Sclérodermies. In: Kahn editor. Les maladies systémiques. Paris: Flammarion 1991:423-63.
50. Alarcon-Segovia D, Ramos-Niembro F, Ibanez de Kasep G, Alcocer J, Tamayo RP. Long-term evaluation of colchicine in the treatment of sclcroderma. J Rheumatol 1979;6:705-12.
51. Steigerwald JC. Colchicine vs placebo in the treatment of progressive systemic sclerosis. In: Black CM, Myers AR, editors. Systemic Sclerosis (Scleroderma). New York: Gower Medical, 1986:415-7.
52. Weiss JS. Antimalarial medications in dermatology: a review. Dermatol Clin 1991 ;9:377-85.
53. Aberer E, Stanek G, Ertl M, Neumann R. Evidence for spirochetal origin of circumscribed scleroderma (morphea). Acta Derm Venereol 1987;67:225-31.
54. Anliker MD, Triieb, RM, Burg G. High dose Penicillin G infusion therapy of scleroderma. Dermatology 1996;193:175-6.
55. Dillon WI, Saed GM, Fivenson DP. Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America. J Am Acad Dermatol 1995;33:617-20.
56. Hulshof MM, Pavel S, Breedveld FC, Dijkmans BAC, Vermeer BJ. Oral calcipotriol as a new therapeutic modality for generalized morphea. Arch Dermatol 1994;130:1290-3.
57. Priestley GC. Proliferation and glycosaminoglycans secretion in fibroblasts from psoriatic skin: differential responses to retinoids. Br J Dermatol 1987; 117:575-83.
58. Bahmer FA, Zaun H. Isotretinoin therapy for progressive systemic sclerosis. Arch Dermatol 1985; 121:308.
59. Maurice PDL, Bunker CB, Dowd PM: Isotretinoin in the treatment of systemic sclerosis. Br J Dermatol 1989;121:367-74.
60. Neuhofer J, Fritsch P. Treatment of localized scleroderma and lichen sclerosus with etretinate. Acta Derm Venereol 1984;64:171-4.
61. Harris ED, Sjoedrsma A. Effect of pénicillamine on human collagen and its possible application to treatment of scleroderma. Lancet 1966;2:996-9.
62. Moynahan EJ. Morphoea (localized cutaneous scleroderma) treated with low-dosage penicillamine (4 cases, includina en coup de sabre). Proc R Soc Med 1973:66:1083-5.
63. Curley RK, MacFarlane AW, Evans S, Woodrow JC. The treatment of linear morphoea with D-penicillamine. Clin Exp Dermatol 1987; 12:56-7.
64. Falanga V, Medsger TA. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol 1990;126:609-12.
65. Keslcr RW, McDonald TD, Balasubramaniam M, Saulsbury FT. Linear scleroderma in children. Am J Dis Child 1981;135:738-40.
66. Steen VD, Blair S, Medsger TA. The toxicity of D-penicillamine in systemic sclerosis. Ann Intern Med 1986; 104:699-705.
67. Bernstein RM, Hall MA, Gostelow BE. Morphoea-like reaction to D-penicillamine therapy. Ann Rheum Dis 1981;40:42-4.
68. Cillery P, Serpier H, Polette M, Bellon G, Clavel C, Wegrowski Y, Birembaut P, Kalis B, Cariou R, Maquart FX. Gamma-interferon inhibits extracellular matrix synthesis and remodeling in collagen lattice culture of normal and scleroderma skin fibroblasts. Eur J Cell Biol 1992;57:244-53.
69. Freundlich B, Jimenez SA, Steen VD, Medsger TA, Szkolnicki M, Jaffe HS. Treatment of systemic sclerosis with recombinant Interferon gamma. A phase I/1I clinical trial. Arthritis Rheum, 1992;35:1134-42.
70. Jansen GT, Barraza DF, Ballard JL, Honeycutt WM, Dillaha CJ. Generalized scleroderma: Treatment with an immunosuppressive agent. Arch Dermatol 1968;97:690-8.
71. Steigerwald JC. Chlorambucil in the treatment of progressive systemic sclerosis. In: Black CM, Myers AR editors. Systemic Sclerosis (Scleroderma). New York: Gower Medical, 1985;423-7.
72. Wörle B, Hein R, Krieg T, Meurer M. Ciclosporin in localized and systemic scleroderma. A clinical study. Dermatoloaica 1990;181:21520.
73. Frances C, Branchet MC, Blétry O, Lefevre C, Boisnic S, Kern P, Godeau P. Skin collagen from scleroderma patients before and after cyclosporin A treatment. Clin Exp Dermatol 1988;13:l-3.
74. Neidner KH. Treatment of localized linear scleroderma with phenytoin. Cutis 1978;22:569-72.
75. Zarafonetis CJD, Dabich L, Skovronski JJ, DeVol EB, Negri D, Yaun W, Wolfe R. Retrospective studies in scleroderma: skin response to potassium para-aminobenzoate therapy. Clin Exp Rheum 1988;6:261-8.
76. Tuffanelli DL. A clinical trial with dimethyl sulfoxide in scleroderma. Arch Dermatol 1966;93:724-5.
77. Scherbel AL, McCormack LJ, Layle JK. Further observations on the effect of dimethyl sulfoxide in patients with generalized scleroderma (progressive systemic sclerosis). Ann NY Acad Sci 1967;141:613-29.
78. Binnick SA, Shore SS, Corman A, Fleischmajer R. Failure of dimethyl sulfoxide in the treatment of scleroderma. Arch Dermatol 1977;113:1398-402.
79. Ayres S, Mihan R. Is vitamin E involved in the autoimmune mechanism ? Cutis 1978;21:321-5.
80. Stava Z, Kobikova M. Salazopyrine in the treatment of scleroderma. Br J Dermatol 1977;96:541-4.
81. Czarnecki DB, Taft EH. Generalized morphoea successfully treated with salazopyrine. Acta Derm Venereol 1982;62:81-2.
82. Neidner KH, Winkelmann RK, Perry HO. Scleroderma: An evaluation of treatment with disodium edetate. Arch Dermatol 1962;86:305-9.
83. Giordano M, Ara M, Cicala C, Valentini G, Chianese U. Griseofulvin for eosinophilic fasciitis. Arthritis Rheum 1980;23:1331 -2.
84. Scharffetter K, Wlaschek M, Hogg A, Bolscn K, Schothorst A, Goerz G, Krieg T, Plewig G. UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 1991;283:506-11.
85. Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y. Decreased collagenase expression in cultured systemic sclerosis fibroblasts. J Invest Dermatol 1994; 103:359-63.
86. Scharffetter-Kochanek K, Goldermann R, Lehmann P, Holzle E, Goerz G. PUVAtherapy in disabling pansclerotic morphoea of children. Br J Dermatol 1995; 133:337-8.
87. Kerscher M, Volkenandt M, Meurer M, Lehmann P, Plewig G, Rocken M. Treatment of localized scleroderma with PUVA bath photochemotherapy. Lancet 1994;343:1233.
88. Kerscher M, Dirschka T, Volkenandt M. Treatment of localised scleroderma by UVA! phototherapy. Lancet 1995:346:1166.
89. Dau PC, Kahaleh MB, Sagebiel RW. Plasmaphcresis and immunosuppressive drug therapy in scleroderma. Arthritis Rheum 1981:24:1128-36.
90. Wach, F, Ullrich H, Schmilz G, Landthaler M, Hein R. Treatment of severe localized scleroderma by plasmapheresis-report of three cases. Br J Dermatol 1995:133:605-9.
91. D'Angelo WA. Progressive systemic sclerosis: management I. Introduction and general commentary. Clin Rheum Dis 1979;5:263.
92. Kottke FJ, Pauley DI, Ptak RA. Rationale for prolonged stretching for correction of shortening of connective tissue. Arch Phys Med Rehabil 1966;47:345-52.
93. Mayro RF, DeLozier JB, Whitaker LA. Facial reconstruction consideration in rheumatic diseases. Rheum Dis Clin North Am 1991:17:943-69.
94. Crickx B, Lazareth I. Sclérodermies. Quel bilan pratiquer ? Ann Dermatol Venereol 1990;117:83-6.